Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2879552 Alone or in Combination With Azacitidine in High Risk MDS
NCT02929498Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2017
- Primary completion
- Jan 2018
- Countries
- 2
01
Overview
Phase 2, open-label trial of GSK2879552 in myelodysplastic syndrome (MDS) (2 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Non-serious Adverse Event (Non-SAE), Serious AE (SAE), Dose Limiting Toxicities (DLT) up to 2 years, Clinical Benefit Rate up to 2.5 years and 1 more. Started Jul 2017; status: terminated.
02
Drugs
GSK2879552
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02929498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929498.